Wutah pendapatan taun lumaku: Larimar Corp (LRMR)

Logo grafis Larimar Corp (LRMR)

Larimar Therapeutics (LRMR) is striving for monopoly leadership in Friedreich's ataxia therapy by implementing the innovative protein nomlabofusp. This chart of rolling year-over-year revenue growth rates demonstrates the development trend, with the indicator holding at 0.00. While geopolitical tensions and sanctions complicate the logistics of biomaterials, strong fund support and dialogue with regulators are helping the company scale its clinical pipeline.

Larimar Therapeutics (LRMR): Wutah pendapatan YoY sajrone 12 wulan kepungkur saka 11.02.2024 nganti 18.11.2026

larimartx.com (LRMR) - rincian metrik lan laporan keuangan

- rega saham lan target rega konsensus:
- indikator kapitalisasi bursa perusahaan:
Analisis kabeh metrik perusahaan:Larimar Pharma
Produk sing diprodhuksi Larimar Therapeutics

This indicator measures the percentage change in revenue over the last twelve months relative to the same period last year, providing an objective assessment of operational expansion rates. For the biopharmaceutical business of Larimar Therapeutics (LRMR), which combines synthesis automation with manual medical oversight, the trailing 12-month sales dynamics versus the prior year serve as a signal of fundamental recovery and genuine commercial progress.